Dr. Gafita on the Rationale to Evaluate 177Lu-PSMA-617 in mCRPC

Andrei Gafita, MD, Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University Munich in Germany, discusses the rationale to evaluate lutetium-177 PSMA-617 (¹⁷⁷Lu-PSMA-617) in metastatic castration-resistant prostate cancer (mCRPC).

Prostate cancer nomograms were developed to inform prognosis, explains Gafita. However, prostate-specific membrane antigen (PSMA)-targeted PET scans have demonstrated increased accuracy in prostate cancer lesion detection versus conventional CT or MRI scans.

Although PSMA is expressed by normal prostate cells, prostate cancer cells overexpress PSMA to a significantly higher degree, making it a good target for therapy, concludes Gafita.